Using error-corrected sequencing for evaluating mutagenicity of molnupiravir in humans
Mutagenesis · 2026
DOI: 10.1093/mutage/geag002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mutagenesis, 2026. Verfasst von Page B McKinzie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, Uni…. Hauptthemen laut MEDLINE: Cytidine, Hydroxylamines, COVID-19 Drug Treatment, Antiviral Agents. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: U.S. Food and Drug Administration's National Center for Toxicological Research, University of Maryland, Baltimore's participation, U.S. Food and Drug Administration’s National Center for Toxicological Research.
Abstract (Originalsprache)
Molnupiravir (MOV) is a prodrug of N-hydroxycytidine (NHC), an analog of the endogenous ribonucleoside cytidine that can be administered orally. MOV is used for treating patients infected by SARS-CoV-2, the coronavirus responsible for COVID-19. MOV and NHC are mutagenic in bacterial and in mammalian cell cultures, yet both chemicals have been negative or equivocal in nonclinical in vivo models of mutagenesis. We designed and validated a novel error-corrected sequencing (ECS) method for detecting single basepair substitutions in tissue samples obtained from genetically heterogeneous humans. The software used for this ECS method is available for free from a public online repository and it is suitable for analysis of in vivo and in vitro derived samples collected in various experimental scenarios. We recruited two groups of patients having COVID-19 1–3 years ago, one group that received a full course of MOV therapy and the other group (matched for age and COVID-19 diagnosis date) that did not receive MOV. Using the ECS method, we determined the frequencies of basepair substitutions in nucleated cells isolated from peripheral blood of the patients. There was no observed difference in the frequency of mutations, the types of mutations, or mutational spectra between the MOV and the control groups. Also, the spectra of mutations in the MOV group did not show any evidence of the mutational signature expected from exposures to MOV or NHC based on data from mammalian cell culture models. Within the limits of this study, the dose of MOV authorized for the treatment of COVID-19 under emergency use authorization appears to have no mutational consequences for treated patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, United States.
- School of Pharmacy, University of Maryland, Baltimore, MD 21201, United States.
ORCID-Profile: Page B McKinzie, Rutu R Valapil, Emily L Heil, James E Polli, Meagan B Myers, Mason G Pearce, Vasily N Dobrovolsky
Förderung
- U.S. Food and Drug Administration's National Center for Toxicological Research
- University of Maryland, Baltimore's participation
- U.S. Food and Drug Administration’s National Center for Toxicological Research
- University of Maryland, Baltimore’s participation
Zitieren
APA
McKinzie, P. B., Valapil, R. R., Heil, E. L., Polli, J. E., Myers, M. B., Pearce, M. G., & Dobrovolsky, V. N. (2026). Using error-corrected sequencing for evaluating mutagenicity of molnupiravir in humans. Mutagenesis. https://doi.org/10.1093/mutage/geag002
Vancouver
McKinzie PB, Valapil RR, Heil EL, Polli JE, Myers MB, Pearce MG, et al. Using error-corrected sequencing for evaluating mutagenicity of molnupiravir in humans. Mutagenesis. 2026. doi:10.1093/mutage/geag002
BibTeX
@article{McKinzie2026,
author = {McKinzie, Page B and Valapil, Rutu R and Heil, Emily L and Polli, James E and Myers, Meagan B and Pearce, Mason G and Dobrovolsky, Vasily N},
title = {Using error-corrected sequencing for evaluating mutagenicity of molnupiravir in humans},
journal = {Mutagenesis},
year = {2026},
doi = {10.1093/mutage/geag002}
}
EUVIMED